Drug intelligence / Profile preview

subunit inactivated influenza vaccine

Development stage
Approved
Lead developer
CSL Seqirus
Modality
Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration
Intramuscular, Intradermal
01

Overview

A **subunit inactivated influenza vaccine** is a type of influenza vaccine prepared by chemically inactivating whole influenza virus, followed by further purification to isolate the major viral surface glycoproteins hemagglutinin (HA) and neuraminidase (NA), while removing other viral components. This process yields a vaccine containing only the essential antigenic proteins needed to stimulate protective immunity. Subunit inactivated influenza vaccines elicit an immune response primarily by inducing the production of antibodies targeting HA and NA. Adjuvants are sometimes added to increase immunogenicity. Subunit vaccines are considered safer and less reactogenic than whole-virion or split-virus vaccines, but may be less immunogenic in individuals not previously exposed to influenza, sometimes requiring multiple doses. These vaccines are widely approved and used for the prevention of influenza in pediatric, adult, and elderly populations, often as trivalent (IIV3) or quadrivalent (IIV4) formulations.

Brand names
InfluvacAgrippalFluvirinAgrifluFlucelvax
Other names
subunit influenza vaccineinfluenza subunit vaccineinactivated subunit influenza vaccine
02

Targets

HA (Hemagglutinin)Neuraminidase

Beyond the preview

Go deeper on subunit inactivated influenza vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on subunit inactivated influenza vaccine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call